CMG Pharmaceutical Co. Ltd Total Assets
CMG Pharmaceutical Co. Ltd total assets. Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) holds total assets worth ₩305.96 Billion KRW (≈ $207.35 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CMG Pharmaceutical Co. Ltd (058820) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CMG Pharmaceutical Co. Ltd (2011–2025)
Total assets of CMG Pharmaceutical Co. Ltd from 2011 to 2025. This chart illustrates how CMG Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. See CMG Pharmaceutical Co. Ltd (058820) share price today for real-time trading data and today's change.
CMG Pharmaceutical Co. Ltd - Asset Composition Analysis
CMG Pharmaceutical Co. Ltd Total Assets Breakdown (December 2025)
CMG Pharmaceutical Co. Ltd total assets breakdown as of December 2025. CMG Pharmaceutical Co. Ltd's total assets of ₩305.96 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.0% |
| Accounts Receivable | ₩34.71 Billion | 11.4% |
| Inventory | ₩29.54 Billion | 9.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩16.20 Billion | 5.3% |
| Goodwill | ₩2.27 Billion | 0.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how CMG Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CMG Pharmaceutical Co. Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CMG Pharmaceutical Co. Ltd's current assets represent 31.1% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 2.0% of total assets in 2025, down from 4.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, unchanged from 5.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 11.4% of total assets.
CMG Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of CMG Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
CMG Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.92 | 1.81 | 12.14 |
| Quick Ratio | 0.63 | 1.49 | 10.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-8.48 Billion | ₩60.21 Billion | ₩134.16 Billion |
CMG Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between CMG Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | ₩305.96 Billion |
| Market Capitalization | $410.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values CMG Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CMG Pharmaceutical Co. Ltd's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CMG Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual total assets of CMG Pharmaceutical Co. Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩305.96 Billion ≈ $207.35 Million |
+0.83% |
| 2024-12-31 | ₩303.44 Billion ≈ $205.63 Million |
+25.34% |
| 2023-12-31 | ₩242.10 Billion ≈ $164.07 Million |
+13.52% |
| 2022-12-31 | ₩213.26 Billion ≈ $144.52 Million |
+7.07% |
| 2021-12-31 | ₩199.17 Billion ≈ $134.98 Million |
+1.95% |
| 2020-12-31 | ₩195.36 Billion ≈ $132.39 Million |
+1.62% |
| 2019-12-31 | ₩192.24 Billion ≈ $130.28 Million |
+68.07% |
| 2018-12-31 | ₩114.38 Billion ≈ $77.51 Million |
+4.39% |
| 2017-12-31 | ₩109.57 Billion ≈ $74.25 Million |
-1.27% |
| 2016-12-31 | ₩110.98 Billion ≈ $75.21 Million |
+96.31% |
| 2015-12-31 | ₩56.53 Billion ≈ $38.31 Million |
-2.64% |
| 2014-12-31 | ₩58.07 Billion ≈ $39.35 Million |
+3.86% |
| 2013-12-31 | ₩55.91 Billion ≈ $37.89 Million |
-2.09% |
| 2012-12-31 | ₩57.11 Billion ≈ $38.70 Million |
+109.15% |
| 2011-12-31 | ₩27.31 Billion ≈ $18.50 Million |
-- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more